SEGMENTS (Tables)

3 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT

The following table summarizes segment financial information by business segment for the three months ended and at June 30, 2025:

(in thousands)		Beyond Air				Beyond Cancer				NeuroNos				Total
Cash, cash equivalents and marketable securities		$	3,056			$	1,777			$	1,630			$	6,463
All other assets			21,241				398				12				21,651
Total assets		$	24,297			$	2,175			$	1,642			$	28,114
Total liabilities			(16,779	)			(530	)			(397	)			(17,706	)
Net assets		$	7,518			$	1,645			$	1,245			$	10,408
Non-controlling interest		$	-			$	330			$	151			$	481
Capital expenditures		$	198			$	-			$	-			$	198

Revenues		$	1,760			$	-			$	-			$	1,760
Cost of revenues			(1,604	)			-				-				(1,604	)
Research and development			(2,234	)			(529	)			(323	)			(3,086	)
Selling, general, and administrative			(3,328	)			(952	)			(407	)			(4,687	)
Loss from operations			(5,406	)			(1,481	)			(730	)			(7,617	)
Interest and finance expense			(548	)			-				-				(548	)
Other non-operating income/(expense)			110				(25	)			2				87
Net loss before income taxes		$	(5,844	)		$	(1,506	)		$	(728	)		$	(8,078	)
Operating activities included in net loss:
Depreciation and amortization		$	795			$	10			$	-			$	805
Stock-based compensation expense		$	1,000			$	512			$	65			$	1,577

Cash used in operations		$	(3,755	)		$	(439	)		$	(332	)		$	(4,526	)
Cash from investing			215				361				-				576
Cash from financing			4,066				-				-				4,066
Impact of exchange rates			148				31				(52	)			127
Net change for the period		$	674			$	(47	)		$	(384	)		$	243

The following table summarizes segment financial information by business segment for the three months ended and at June 30, 2024:

(in thousands)		Beyond Air				Beyond Cancer				NeuroNos				Total
Cash, cash equivalents and marketable securities		$	13,158			$	8,216			$	-			$	21,374
All other assets			24,357				769				-				25,126
Total assets		$	37,515			$	8,985			$	-			$	46,500
Total liabilities			(27,722	)			(1,078	)			-				(28,801	)
Net assets		$	9,793			$	7,907			$	-			$	17,699
Non-controlling interest		$	-			$	1,570			$	-			$	1,570
Capital expenditures		$	2,650			$	23			$	-			$	2,673

Revenues		$	683			$	-			$	-			$	683
Cost of revenues			(1,016	)			-				-				(1,016	)
Research and development			(4,078	)			(1,930	)			-				(6,009	)
Selling, general, and administrative			(4,878	)			(2,361	)			-				(7,239	)
Loss from operations			(9,289	)			(4,291	)			-				(13,580	)
Interest and finance expense			(964	)			-				-				(964	)
Other non-operating income/(expense)			1,467				22				-				1,489
Net loss before income taxes		$	(8,786	)		$	(4,269	)		$	-			$	(13,055	)
Operating activities included in net loss:
Depreciation and amortization		$	719			$	17			$	-			$	736
Stock-based compensation expense		$	1,950			$	1,429			$	-			$	3,379

Cash used in operations		$	(7,500	)		$	(2,680	)		$	-			$	(10,180	)
Cash used in investing			5,405				(2,290	)			-				3,114
Cash from financing			(264	)			-				-				(264	)
Impact of exchange rates			21				90				-				111
Net change for the period		$	(2,338	)		$	(4,880	)		$	-			$	(7,218	)